UNIVERSITY OF DEUSTO<\/strong><\/p>\n18:00h – 18:30h |<\/span><\/strong> Registration and credential collection<\/p>\n18:30h – 19:00h |<\/span><\/strong> Opening of the congress<\/p>\n19:00h – 20:30h |<\/span><\/strong> Informational session<\/p>\nThe enormous potential of AI, quantum computing, new advanced therapies, and recent advances in biology in the healthcare sector over the coming years.<\/strong><\/p>\n\n- Mikel Renteria<\/strong> (Fundaci\u00f3n The Walk On Project)<\/strong><\/em><\/li>\n
- Salvador Mart\u00ednez<\/strong> (Instituto de Neurociencias de Alicante-CSIC)<\/strong><\/em><\/li>\n
- Fernando Corrales (CSIC)<\/em><\/strong><\/li>\n
- Ander Ramos (Tecnalia)<\/em><\/strong><\/li>\n
- Juli\u00e1n Isla (Microsoft \/ Foundation 29)<\/em><\/strong><\/li>\n<\/ul>\n<\/div><\/div><\/div>
<\/div><\/div><\/div>
June 11, 2026<\/h3>\n<\/div><\/div>
TECHNOLOGICAL FRONTIER<\/h3>\n<\/div><\/div>
New technologies applied to myelin-related disorders<\/h4>\n<\/div><\/div><\/div>UNIVERSITY OF DEUSTO<\/strong><\/p>\n08:00h – 09:00h | <\/span><\/strong>Registration and credential collection<\/p>\n9:30h – 10:30h | <\/strong><\/span>Presentations (15′ each)<\/em><\/p>\n\n- Salvador Mart\u00ednez<\/strong> (Instituto de Neurociencias de Alicante-CSIC)<\/strong>:<\/strong><\/em> ‘Biomodels’<\/li>\n
- Fabio Cavaliere (Achucarro Basque Center for Neuroscience):<\/em><\/strong> ‘Organoids’<\/li>\n
- Fernando Corrales (CSIC):<\/em><\/strong> ‘Proteomics’.<\/li>\n
- Matxalen Uriarte (Universal Omics):<\/em><\/strong> ‘AI Metabolomics’.<\/li>\n<\/ul>\n
10:30 – 11:00 |<\/span><\/strong> Coffee break<\/p>\n11:00h – 11:45h | <\/span><\/strong>Presentations (15′ each)<\/em><\/p>\n\n- Aitor Moreno (LKS Next)<\/em>:<\/strong> ‘AI and Quantum Computing Applied to the Scientific Process’<\/li>\n
- Ander Ramos (Tecnalia)<\/em>:<\/strong> ‘BCI’.<\/li>\n
- Juli\u00e1n Isla (Microsoft \/ Foundation 29)<\/em>:<\/strong> ‘AI in Clinical Practice + EMA’<\/li>\n<\/ul>\n
11:45h – 13:00h |<\/span><\/strong> Round table<\/p>\nThe Potential and Limitations of New Technologies in Healthcare<\/strong><\/p>\nHow can we harness the enormous potential of today\u2019s technologies? How can we build consensus and break down barriers? What safeguards should be put in place to prevent potential negative effects?<\/p>\n
\n- Moderators: <\/strong>Mikel Renteria and Salvador Mart\u00ednez.<\/li>\n
- Panel: <\/strong>Fabio Cavaliere, Fernando Corrales, Matxalen Uriarte, Aitor Moreno, Ander Ramos, Juli\u00e1n Isla<\/li>\n<\/ul>\n
13:00h – 15:00h | <\/span><\/strong>Cocktail lunch<\/p>\n<\/div><\/div><\/div>June 11, 2026<\/h3>\n<\/div><\/div>
GENE FRONTIER<\/h3>\n<\/div><\/div>
Gene therapy in myelin-related diseases<\/h4>\n<\/div><\/div><\/div>UNIVERSITY OF DEUSTO<\/strong><\/p>\n14:30h – 15:00h | <\/span><\/strong>Registration and credential collection<\/p>\n15:00h – 17:30h | <\/span><\/strong>Presentations (30′ each)<\/em><\/p>\n\n- Bernard Zalc (Institut du Cerveau-ICM)<\/em>:<\/strong> ‘Research on the Toxicity of PFAS (Perfluoroalkyl Substances) on Myelin Stability’<\/li>\n
- P. J. Orchard (University of Minessota)<\/em>:<\/strong> ‘Gene therapy for X-linked adrenoleukodystrophy (X-ALD)’<\/li>\n
- Nathalie Cartier (Paris Brain Institute – ICM)<\/em>: <\/strong>‘Gene delivery to the CNS’<\/li>\n
- Ram\u00f3n Mart\u00ednez-M\u00e1\u00f1ez<\/strong> (UPV Universitat Polit\u00e8cnica de Val\u00e8ncia)<\/em>: <\/strong>‘Lipid microvesicles: new vectors for gene therapy’<\/li>\n
- C\u00e9sar Trigueros (Viralgen)<\/em>: <\/strong>‘Gene design and delivery using vectors in the context of the CNS’<\/li>\n<\/ul>\n
17:30h – 18:00h | <\/span><\/strong>Coffee break \/ Posters<\/p>\n18:00h – 18:30h | <\/span><\/strong>Presentations<\/p>\n\n- Jos\u00e9 Mar\u00eda Moraleda (TERAV)<\/em>:<\/strong> ‘The Spanish model for advanced therapies‘<\/em><\/li>\n<\/ul>\n
18:30h – 19:30h | <\/span><\/strong>Round table<\/p>\nTranslational research and clinical challenges in gene therapy for demyelinating diseases.<\/strong><\/p>\nBiological and pathological challenges. Vector technology, transport, and delivery. Clinical trial designs. Safety and long-term monitoring. Ethical and social considerations.<\/p>\n
\n- Moderators: <\/strong>Bernard Zalc (Basic research perspective)<\/em> and Nathalie Cartier (Clinical perspective)<\/em>.<\/li>\n